Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program-Reference-Cited by-同舟云学术

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Published:2017-11 Issue:11 Volume:28 Page:2715-2724
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Leduc C.,Merlio J.P.,Besse B.,Blons H.,Debieuvre D.,Bringuier P.P.,Monnet I.,Rouquette I.,Fraboulet-Moreau S.,Lemoine A.,Pouessel D.,Mosser J.,Vaylet F.,Langlais A.,Missy P.,Morin F.,Moro-Sibilot D.,Cadranel J.,Barlesi F.,Beau-Faller M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/11/2715/21556060/mdx404.pdf

Reference26 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO);ESMO Open;2024-06

2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations;Frontiers in Immunology;2024-05-07

3. Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18;Translational Lung Cancer Research;2024-04

4. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

5. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study;BMC Cancer;2023-10-16